dc.contributor.authors |
Apaydin, M.; Kazan, E. D.; Beysel, S.; Sari, A.; Ozgul, E.; Cengiz, H.; Demirci, T.; Yilmazer, M. |
|
dc.date.accessioned |
2022-12-20T13:24:59Z |
|
dc.date.available |
2022-12-20T13:24:59Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
1128-3602 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/99138 |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
- OBJECTIVE: Polycystic ovary syndrome (PCOS) is the most common endo-crinological disorder in women of reproduc-tive age, often accompanied by high androgen levels, irregular menstrual cycles and polycys-tic ovaries. In addition, patients with PCOS al-so |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.subject |
Pharmacology & Pharmacy |
|
dc.subject |
Cardiometabolic risk |
|
dc.subject |
Insulin resistance |
|
dc.subject |
Polycystic ovary syndrome |
|
dc.subject |
VAI |
|
dc.title |
The novel predictor of metabolic risk in patients with polycystic ovary syndrome: could it be the visceral adiposity index? |
|
dc.identifier.volume |
26 |
|
dc.identifier.startpage |
7182 |
|
dc.identifier.endpage |
7187 |
|
dc.relation.journal |
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES |
|
dc.identifier.issue |
19 |
|
dc.contributor.author |
Apaydin, M. |
|
dc.contributor.author |
Kazan, E. D. |
|
dc.contributor.author |
Beysel, S. |
|
dc.contributor.author |
Sari, A. |
|
dc.contributor.author |
Ozgul, E. |
|
dc.contributor.author |
Cengiz, H. |
|
dc.contributor.author |
Demirci, T. |
|
dc.contributor.author |
Yilmazer, M. |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|